Discover and read the best of Twitter Threads about #BetaDrugs

Most recents (3)

#betadrugs

AR FY21-22

MY TWO CENT .

If you like please RT

Second wave of COVID 19 impacted lives ,bussiness across the board.

We have also started to see inflation across economic in the world, interest rate increase & with ukrarian war conflict,supply chain constraints.
2/n
Even the world experienced chaos and disruption, we delivered our highest growth .

FY22 revenues grew by 58% to 183.84 crores while consolidated EBITDA grew by 72% to Rs 43.5 crore from 25.24 compared with the year ago period. EBITDA margins expanded to 23.6 % from 21.7%
3/n
Net profit too increased by 112% to Rs 24.8crores from Rs 11.7 crores compared with the same period a year ago.
#betadrugs commands a strong position in the Indian market with more than 112 SKUs and its products are available across all major Corporate & Govt hospitals.
Read 14 tweets
Beta Drugs – SME Co

Co Overview: Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. As per Co’s website, it is aiming to launch 25 new products by 2026. It's manufacturing facilities consist of an API & formulation plants
#stock
Leadership: After the demise of Late Shri Vijay Batra (Founder), the next generation of the Family has taken over the Leadership Role – Mr. Rahul Batra Chairman & Managing Director (Looks very aggressive in strategies to Me)

#StockMarket
#stock
#stockstowatch
Business Overview:

1. Domestic Market: Beta Drugs develops and commercialize high quality & cost effective complex oncology drugs. Beta Drugs has a leadership position in Indian Oncology Market with 100 SKU's.

#StocksInFocus
#StockMarket
#stock
Read 10 tweets
On 29th April, @niftygranmaster added #BetaDrugs to his portfolio. The first SME stock. He had posted on 24th about the potential of companies, working on cancer cure. Let’s now take a deeper look at Beta Drugs and review its growth potential
2/ The company’s growth has indeed taken off in FY22.

FY 2018 - Rs.50 Crores

FY 2019 - Rs.64 Crores

FY 2020 - Rs.90 Crores

FY 2021 - Rs.116 Crores

FY 2022 - Rs.183 Crores

Net profit in FY22 more than doubled to Rs.25Crore with EPS at Rs.26.
3/ Beta Drugs had fully acquired Adley Formulation Pvt Ltd (AFPL) and Adley Lab Ltd (ADL) resulting in backward integration of APIs & other raw materials. This has made key difference in its operating margins and revenues.
Read 16 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!